<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 22, 1996
Roberts Pharmaceutical Corporation
----------------------------------------------------------
(Exact name of registrant as specified in its charter)
New Jersey 1-10432 22-2429994
- ---------------- ---------------- -----------------
(State or other (Commission (IRS Employer
jurisdiction File Number Identification
of incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive office, including zip code)
Registrant's telephone number, including area code: (908)389-1182
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
<PAGE>
Item 5. Other Events
------------
On July 22, 1996, Roberts Pharmaceutical Corporation announced that the
Health Protection Branch, Canada has notified it that Eminase(R) the Company's
life saving thrombolytic therapy, has been approved for that market.
Eminase is a cardiovascular agent which Roberts currently markets in the
U.S., U.K., and elsewhere for the treatment of acute myocardial infarction
(heart attack). Eminase is indicated for use in the dissolution of thrombi
(clots) obstructing coronary arteries; to improve ventricular function and to
reduce mortality associated with acute myocardial infarction. Compared with
other thrombolytic therapies that require administration by infusion over 60 to
90 minutes or longer, Eminase is administered in minutes by direct injection.
Roberts acquired the worldwide rights to Eminase from SmithKline Beecham in
1995 and has since been positioning the product for international market
opportunities.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Roberts Pharmaceutical Corporation
----------------------------------
(Registrant)
By: /s/ Anthony A. Rascio
------------------------------
Anthony A. Rascio
Vice President
Date: July 26, 1996
